Vertex Pharmaceuticals Inc.
Large Cap · Healthcare · Biotechnology
$505.55−$10.89 (-2.11%)
Vertex Pharmaceuticals Inc.
Large Cap · Healthcare · Biotechnology
$505.55−$10.89 (-2.11%)
Stock analysis
Get the AI take on VRTX
Track it to unlock the price chart, verdict and what could change it.
- ✓Live price chart
- ✓A clear accumulate, trim or avoid call
Free to track. No card required.
Stock Fundamentals & Key Indicators
52-week range
Low$362.50
High$533.67
Today $505.55
RSI (14)
56.5Neutral
03070100
Overall score
73/100
See the full financial picture
Open the five-year record, valuation checks and Wall Street view behind these scores.
- ✓5 years of revenue, profit and cash flow
- ✓Valuation and balance-sheet checks
- ✓Business and geographic mix
- ✓Analyst targets and recommendation trend
Free for 3 days, then $9/mo. Cancel anytime.
Analyst Rating and Sentiment
Analyst price targets
Lowest
$350
Current price
$505.55
Median target
$570
Highest
$672
LowHigh
Operating Record
Revenue
Business mix
Jun 30, 2026Trikafta and Kaftrio100.0% · $10.1B
Geographic mix
Jun 30, 2026United States62.6% · $7.9B
Europe28.9% · $3.6B
Other8.5% · $1.1B
What's working
- Cash exceeds debt by $11.7B, leaving a net cash buffer, a good sign.
- ROIC: Money put back into the business keeps coming back out as profit, a hallmark of a durable moat.
What to watch
- Forward P/E: The price already assumes strong earnings growth that still has to show up.
- Price / sales: Revenue alone can't justify this price; profits need to catch up fast.
What the market charges
Forward P/E
Needs attention · 24% above avg
25.41x
Price / sales
Rich · Priced well above what its revenue alone supports
10.18x
Price / FCF
Reasonable · Priced a bit rich against its cash flow
33.77x
EV / EBITDA
Rich · Operating earnings don't yet support this price
22.85x
How efficiently it compounds
ROIC
Strong · Comfortably clears the bar for efficient capital use
28.8%
ROE
Favorable · 24.2% - strong capital efficiency
23.5%
Debt / equity
Favorable · 0.10 - strong leverage
0.10x
Current ratio
Strong · Comfortable room to cover bills due within a year
3.19x
Peer Comparison
| Company | Mkt cap | P/E | Rev growth | Score |
|---|---|---|---|---|
| $128.19B | 29.4 | +10.2% | 73 |
 | $11.53B | 22.0 | +19.7% | 78 |
 | $4.60B | 13.9 | +13.5% | 77 |
 | $33.87B | 35.4 | +15.5% | 77 |
 | $1.11T | 40.1 | +49.6% | 76 |